Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to selective GLP-1 agonists (semaglutide) and basal insulins (degludec, glargine) in patients with type 2 diabetes.
Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1) to improve how your body handles sugar and fat. Clinical trials show it lowers blood sugar and reduces body weight more effectively than standard diabetes medications like insulin or other GLP-1 drugs like semaglutide. It is prescribed for adults with type 2 diabetes or obesity, starting at a low dose to minimize stomach upset, and increasing over time. It is not suitable for people with a specific family history of thyroid cancer.
Compared to the selective GLP-1 receptor agonist semaglutide in patients with T2DM (SURPASS-2 clinical trial), tirzepatide was superior in decreasing in a dose-dependent manner the mean glycated hemoglobin (HbA1c) levels (up to 2.3% reduction from baseline)... Furthermore, compared to insulin degludec (SURPASS-3) and insulin glargine (SURPASS-4), once-weekly tirzepatide has shown greater reductions in HbA1c and body weight with lower adverse effects including hypoglycemia.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS-1 through 5, SURMOUNT-1) cited in the review.
Source
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
Ioannis Lempesis et al. · Metabolism Open · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →